Trylon Corporation, The

Proposed Ticker: TRLN		970 W. 190th Street, Suite 900
Exchange: NASDAQ-National Market		Torrance, California 90502
Industry: Manufacturing		(310) 327-8820

All share information is proposed
Type of Shares:	Common Shares	Filing Date:	8/9/96
U.S. Shares Filed:	0	Filing Price:	-
Non-U.S. Shares Filed:	0	Offering Amount:	$40,000,000
Primary Shares:	0	Expenses:	-
Secondary Shares:	0	Shs Out After:

Manager	Tier	Phone
Donaldson, Lufkin & Jenrette Securities Corp.	Lead Manager	(212) 504-4525

	Audited Income	Latest Unaudited Income	Prior Unaudited Income		Balance Sheet
	12/31/95	3/31/96	3/31/95		3/31/96
Revenue:	$0.63	$0.04	$0.05	Assets:	$1.75
Net Income:	-$1.01	-$0.40	-$0.44	Liabilities:	$0.47
EPS:	-$11.70	-$4.65	-$5.06	Equity:	$1.27
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year

Business Description

The company is an innovative medical products company that has pioneered the use of chemical light technology in diagnostic and other medical applications. The company's first product, PAP PLUS SPECULOSCOPY, combines the company's patented visual examination, SPECULOSCOPY, with standard Pap smear, into a simple cervical screening test for women. Speculoscopy, which can be performed by a wide range of health care practititioners at low cost, visually illuminates cervical abnormalities, which may include cancer and precancer, during a routine pelvic examination. The company received clearance from the FDA in December 1995 to market PPS for primary cervical screening. The company's objective is to have PPS to become a "standard of care" for primary cervical screening worldwide. The company has scheduled major United States and international product launches of PPS during 1994.

Use of Proceeds

The proceeds from the proposed offering will be used to fund the PPS domestic marketing marketing campaign, research and development activities, capital expenditures and general corporate purposes.

Last updated: 10/28/96